Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated MelanomaJames Larkin, Antoni Ribas, Paolo A. Ascierto et al.|New England Journal of Medicine|2014Cited by 2k
Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trialPaolo A. Ascierto, James Larkin, Grant A. McArthur et al.|The Lancet Oncology|2016Cited by 1k
Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trialReinhard Dummer, Keith T. Flaherty, Dirk Schadendorf et al.|The Lancet Oncology|2017Cited by 491
Dermoscopic Evaluation of Amelanotic and Hypomelanotic MelanomaScott W. Menzies, Robert H. Johr, Juergen Kreusch et al.|Archives of Dermatology|2008Cited by 304
Vismodegib in patients with advanced basal cell carcinoma: Primary analysis of STEVIE, an international, open-label trialNicole Basset‐Séguin, Johan Hansson, Axel Hauschild et al.|European Journal of Cancer|2017Cited by 284